Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes
Open Access
- 1 April 2020
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 189 (5) , E211-E213
Abstract
No abstract availableKeywords
Funding Information
- Leukemia and Lymphoma Society (2400‐13)
- University of Florida
This publication has 9 references indexed in Scilit:
- A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid LeukemiaCancers, 2019
- Acute myeloid leukemia in the vascular nicheCancer Letters, 2016
- Chemosensitizing AML cells by targeting bone marrow endothelial cellsExperimental Hematology, 2016
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- Functional integration of acute myeloid leukemia into the vascular nicheLeukemia, 2014
- Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agentLeukemia, 2012
- Leukemia regression by vascular disruption and antiangiogenic therapyBlood, 2010
- The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell deathBlood, 2008
- Oxidative Metabolism of Combretastatin A-1 Produces Quinone Intermediates with the Potential To Bind to Nucleophiles and To Enhance Oxidative Stress via Free RadicalsChemical Research in Toxicology, 2007